Objectives: Evaluate the diagnostic accuracy of the APPY1TM biomarker panel, previously described for use in pediatric patients, for identifying adult ED patients with abdominal pain who are at low risk of acute appendicitis. Methods: This study prospectively enrolled subjects N18 years of age presenting to seven U.S. emergency departments with b 72 hours of abdominal pain suggesting possible acute appendicitis. The APPY1 panel was performed on blood samples drawn from each patient at the time of initial evaluation and results were correlated with the final diagnosis either positive or negative for acute appendicitis. Results: 431 patients were enrolled with 422 completing all aspects of the study. The APPY1 biomarker panel exhibited a sensitivity of 97.5% (95% CI, 91.3-99.3%), a negative predictive value of 98.4% (95% CI, 94.4-99.6%), a negative likelihood ratio of 0.07 (95% CI, 0.02-0.27), with a specificity of 36.5% (95% CI, 31.6-41.8%) for acute appendicitis. The panel correctly identified 125 of 342 (36.6%) patients who did not have appendicitis with 2 (2.5%) false negatives. The CT utilization rate in this population was 72.7% (307/422). Of 307 CT scans, 232 were done for patients who did not have appendicitis and 79 (34%) of these patients were correctly identified as negative with "low risk" biomarker panel results, representing 26% (79/307) of all CT scans performed. Conclusion: This biomarker panel exhibited high sensitivity and negative predictive value for acute appendicitis in this prospective adult cohort, thereby potentially reducing the dependence on CT for the evaluation of possible acute appendicitis.
Introduction
Abdominal pain is the leading cause of emergency department (ED) visits for adult patients, with acute appendicitis being one of the most common acute surgical diagnoses [1] . While appendicitis has a peak incidence in the second decade of life, appendectomy is the third most common abdominal surgical procedures across all age groups [2, 3] .
The diagnosis of acute appendicitis in adult patients is largely dependent on computed tomography (CT) scanning, especially when appendicitis or other acute surgical diagnoses are being considered [4] [5] [6] [7] [8] [9] . Abdominal CT is an invaluable tool for the evaluation of abdominal pain but has several well recognized disadvantages including radiation exposure, risk of contrast induced nephropathy, and cost [10] [11] [12] [13] [14] . Additionally, the time required for performance of CT, particularly when oral contrast is needed, may add substantially to ED length of stay, a contributing factor to ED crowding [15, 16] . While the precise anatomical information provided by CT outweighs these disadvantages for certain patients, over-utilization of abdominal CT scanning is a recognized problem [17] [18] [19] [20] [21] . Yet at the same time acute appendicitis is the second most common diagnosis leading to malpractice claims against emergency physicians after acute myocardial infarction [22] . Therefore, new strategies are needed to safely evaluate for appendicitis while limiting CT utilization.
We have previously described a biomarker panel, the APPY1™ test, consisting of white blood cell count (WBC), C-reactive protein (CRP), and myeloid related protein 8/14 (MRP 8/14) that had high sensitivity and negative predictive value for acute appendicitis in pediatric and adolescent ED patients with abdominal pain [23, 24] . This biomarker panel correctly identified 38% of patients who did not have acute appendicitis, thereby offering the potential to avoid CT scanning and facilitate the rapid diagnostic evaluation and disposition for a substantial portion of patients who did not have acute appendicitis [24] . Following these promising results in the pediatric population, we evaluated the APPY1 test in adults. The purpose of this study was to assess the diagnostic performance of this biomarker panel in adult ED patients with abdominal pain being evaluated for acute appendicitis.
Methods
This study was a prospective observational industry sponsored investigation to evaluate the performance of a previously described biomarker panel, the APPY1 test. The panel, originally developed for use in pediatric and adolescent patients, was evaluated here in an adult population presenting to the ED with abdominal pain suggesting possible acute appendicitis.
This study was conducted at seven general academic and community hospital emergency departments (EDs) across the United States between April 2014 and September 2014 and was sponsored by Venaxis Inc., Castle Rock, CO. All sites obtained Institutional Review Board (IRB) approval prior to study initiation and all participating patients provided written consent prior to enrollment in the study.
The study cohort was a convenience sample of patients aged 18 years and older presenting to participating EDs with abdominal pain and other symptoms suggesting possible acute appendicitis. Patients were eligible for inclusion whenever the treating physician considered appendicitis to be in the initial differential diagnosis and they met the inclusion and exclusion criteria below.
Patients were screened during times of study staff availability, primarily weekday and evening hours, based on chief complaint and presenting symptoms. Patients who met inclusion criteria were approached for participation and those who agreed to participate were enrolled prospectively based on initial symptoms and clinical assessment. Patients who provided consent had blood samples drawn for testing of the biomarker panel described below. Treating physicians were blinded to the biomarker panel results. Any and all decisions regarding evaluation, other laboratory testing, imaging, and treatment were determined solely by the treating physicians independent of study participation.
Inclusion criteria were: age≥ 18 years, right lower quadrant or generalized abdominal pain with other signs and symptoms suggesting acute appendicitis as part of the differential diagnosis, duration of symptoms ≤72 h, and the ability to obtain informed consent.
Exclusion criteria were a history of previous appendectomy, metastatic cancer, bleeding disorder, or renal failure requiring dialysis. Patients were excluded if they were treated with any immunosuppressive medications within the preceding 28 days or systemic steroids within the preceding 14 days. Other exclusions included abdominal trauma or invasive abdominal procedures within the two weeks prior to study enrollment. Patients were also excluded if they were prisoners of an adult detention center, if they participated in other research protocols within the prior 30 days, or if life expectancy was less than six months.
The biomarker panel under study consists of the combined values of total white blood cell count (WBC), plasma C-reactive protein (CRP) level and plasma myeloid related protein 8/14 (MRP 8/14 or calprotectin) level in a proprietary mathematical algorithm expressed as 0.1177(WBC k/μl) + 0.0202(CRP μg/ml) + 1.6(MRP 8/14 μg/ml) + 2.4372 = A, with A being a single numerical value as previously described [23, 24] .
WBC values from each patient were obtained using the standard clinical laboratory process and hematology analyzer at each participating site. Whole blood samples for additional biomarker measurement of CRP and MRP 8/14 levels were drawn into K2EDTA tubes either by direct venipuncture or from an established peripheral IV catheter using standardized draw and flushing procedures for blood sampling from existing IV catheters. Blood draws for WBC determinations and for biomarker testing were required to be no more than 1 h apart.
The samples drawn for CRP and MRP 8/14 measurement were processed within one hour of blood draw by centrifugation at 1300 G for 10 min followed by collection of the plasma layer with careful attention to avoid the buffy coat. This centrifugation and plasma collection process was repeated a second time after which the plasma samples were frozen at minus 70 degree Celsius or colder and shipped frozen to Venaxis for testing. After thawing, the CRP and MRP 8/14 concentrations were then measured using the APPY1™ Test System. The subjects WBC value recorded at the time of the initial encounter was then entered into the APPYReader combining the WBC value with the CRP and MRP 8/14 concentrations obtained internally, calculating the APPY1 test result.
Data were collected by study staff using standardized case report forms (CRFs). Study staff included physicians, physician assistants, research nurses, and clinical research coordinators. Data were collected by a combination of direct interview of patients and clinicians as well as subsequent ED chart review. The data collected included demographic information, clinical symptoms, past medical history, comorbid conditions, and preceding treatment. Clinical data points collected included time of onset, reported duration of illness, time of ED presentation, symptoms, signs, and physical findings. The treating clinician's gestalt of the likelihood of acute appendicitis, classified as low, medium, or high, was also collected. Timing of blood draw and processing, surgery, and abdominal ultrasound and/or CT imaging along with imaging results were recorded, as was disposition and discharge diagnosis for all patients. Surgical pathology reports for those who had appendectomy, and results of follow-up phone calls at 14 days (+/− 3 days) for all patients who did not have appendectomy at the time of initial evaluation were also recorded. In compliance with the International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines, study site staff entered data into an electronic data capture system. Missing data points were recorded as not available and excluded from analysis. CRFs were verified for accuracy by independent study monitors.
Primary outcome measures were the results of the biomarker panel (the index test), and the presence or absence of appendicitis (the reference standard) for each patient. The biomarker panel results were dichotomized as low risk vs. inconclusive (not low risk) with a predefined low risk cut off of b4, as derived and validated per previous pediatric reports [23, 24] . Biomarker panel results ≥4 were considered inconclusive. The presence or absence of appendicitis was defined by the onsite clinical pathologist's final interpretation of the surgical specimen of the appendix for those patients undergoing appendectomy, and clinical diagnosis for those who did not have appendectomy. Those patients who did not have an appendectomy at the time of initial evaluation were contacted by telephone at 2 weeks (+/− 3 days) after discharge to confirm the initial clinical diagnosis. Patients who reported resolution of symptoms and the absence of subsequent diagnosis of acute appendicitis were defined as negative for appendicitis. Patients who reported appendectomy subsequent to the initial visit were also defined as negative or positive for appendicitis based on the final pathologic diagnosis. Treating clinicians and pathologists were blind to the biomarker panel results.
The primary study endpoints were the diagnostic accuracy of the biomarker panel as measured by the sensitivity (Se) and specificity (Sp) with 95% CI using the predetermined negative cut-off of b 4 in identifying those patients without appendicitis. Secondary endpoints were negative and positive predictive values, likelihood ratios, and imaging data analysis. Measurements, endpoints, data collection, and reporting of results follow the guidelines of the Standards for Reporting of Diagnostic Accuracy (STARD) initiative [25, 26] .
This study was sized in order to provide reasonable estimates of the performance of the biomarker panel in adults. Based on the performance observed in the large study of children, sensitivity was assumed to be greater than 96.5% 7 . A lower 95% lower confidence limit for sensitivity of at least 90% could be achieved with 75 adults with appendicitis. Based on an assumed prevalence of approximately 20%, enrollment of at least 400 subjects was targeted. A final analysis population of 422 was achieved. Data analysis was performed using appropriate methodology with JMP Pro (v12, SAS Institute, Cary, NC).
Results
From April 2014 through September 2014 adult patients presenting to the EDs of seven participating institutions with symptoms suggesting acute appendicitis as part of their differential diagnosis were approached for consent to participate. There were 431 patients enrolled, of whom 9 were excluded for ineligibility, lack of adequate samples, improper sample processing, or lost to follow-up, leaving 422 patients in the final study sample.
The final study sample of 422 patients had a median patient age of 31 years (IQR: 24-44). The population was 65% female and the overall prevalence of appendicitis in the sample was 19.0% (80/422), with a prevalence of 24.8% in male patients and 15.8% in female patients. The observed range of biomarker panel results was 2.9 to 6.9. Patient demographics and characteristics are displayed in Table 1 . Enrollment, exclusions, diagnostic pathway, imaging, treatment, and disposition information for the patient sample are shown in Fig. 1 Table 2 .
The overall performance characteristics of the biomarker panel are displayed in Table 3 along with the results of exploratory subgroup analysis of the diagnostic accuracy by duration of symptoms, patient age, gender, and clinical risk. Detailed imaging, diagnostic, and treatment data comparing patients with negative versus inconclusive biomarker panel results are shown in Fig. 2 , and imaging utilization data is provided in Table 4 . The CT utilization rate in this population was 72.7% (307/422). Of 307 CTs, 232 were done for patients who did not have appendicitis and 79 (34%) of these patients were correctly identified as negative with low risk biomarker panel results, representing 26% (79/307) of all CT scans performed. The two false negative patients were female, both with symptoms between 13-24 h in duration. The first was 19 years of age, classified as moderate clinical risk, with an APPY1 result of 3.8. The second was 28 years old, high clinical risk, with an APPY1 result of 3.9. One patient was diagnosed by CT scan, the other by MRI, and both had subsequent appendectomy with pathologic confirmation of acute appendicitis.
There was a single patient classified as acute appendicitis based on imaging and clinical diagnosis without pathologic confirmation. This patient had perforated appendicitis by CT scan and was treated with antibiotics without surgery. There was a second patient treated with antibiotics alone who was initially diagnosed as appendicitis by CT scan.
However, this patient did not have an appendectomy and the final discharge diagnosis was pneumonia. This patient was classified as negative for acute appendicitis and the CT was considered a false positive. Both of these patients had inconclusive biomarker results, therefore inclusion or elimination of these two patients from the analysis did not materially affect the results.
As a basis for comparison, we performed a post hoc analysis to calculate the performance characteristics for the combination of WBC and CRP, considered negative when both were below a designated cut off and positive if either one was above that cut off. We found that using a cut off that combined a normal WBCb 11 k/μl with normal CRPb 0.8 mg/dl, the sensitivity was also 97.5% (95% CI, 91.3-99.3%) with 2 (2.5%) false negative patients, identical to the biomarker panel. The negative predictive value was 98.8% (95% CI, 95.9-99.7%), with a negative likelihood ratio of 0.05 (95% CI, 0.01-0.20) and a specificity of 50.0% (95% CI, 44.7-55.3%). The greater specificity resulted in identification of 110 of 232 patients who had CT scans but did not have appendicitis.
Discussion
This biomarker panel, previously reported to identify pediatric and adolescent ED patients with abdominal pain who were at low risk of AA+ = acute appendicitis, AA-= no acute appendicitis acute appendicitis, showed similar test characteristics in adult patients with high sensitivity and negative predictive value, 97.5% and 98.4% respectively, and a specificity of 36.5% [23, 24] . The panel identified more than one third of patients who did not have acute appendicitis. The performance of WBC and CRP as individual markers and in combination has been explored previously with varying results [27] [28] [29] . In this sample the combined cut-offs WBCb 11 k/μl and CRP b 0.8 mg/dl provided similar sensitivity and negative predictive value as the biomarker panel with better specificity, identifying half of patients without appendicitis. However, this must be interpreted with caution as a post hoc analysis. Additionally, the CRP values were taken from the APPY1 test and it is unclear how these values correlate with the variety of commercially available CRP assays that are currently in clinical use.
These results suggest that adult ED patients with abdominal pain for whom acute appendicitis is the primary concern might have imaging deferred in favor of clinical observation in the setting of low risk results on the APPY1 test or with negative results for both WBC and CRP. For patients with a broader differential diagnosis, the early exclusion of appendicitis may affect subsequent decisions regarding initial treatment, what type of imaging (if any) is most appropriate, or the need for surgical consultation.
Another important finding in this study is that CT utilization rates were substantially higher in this adult population than in two previous pediatric studies despite similar inclusion and exclusion criteria [23, 24] . While overall imaging rates (US, CT, and MRI) in this study were comparable to the two previous pediatric studies (87.7%, 78.9% and 84.1% respectively), the CT utilization rate in this adult study was 72.7%, compared to 36.8% and 29.5% for pediatric patients [23, 24] . This likely relates to the fact that many authorities advocate US as the preferred initial imaging modality for pediatric appendicitis while acute appendicitis is rarely diagnosed by US in adults [20] [21] [22] [30] [31] [32] . Only one of 80 cases of acute appendicitis in this adult population was diagnosed by US. As shown in Table 4 , US was used primarily in female patients, presumably because US is the preferred imaging modality for gynecologic pathology. Additionally, it was unusual for an adult patient to have an appendectomy without first having imaging (only 2/80, 2.5%), with most patients having pre-operative CT (75/80, 93.8%). By contrast, 28.5% of pediatric patients with acute appendicitis in our previous study had appendectomy without imaging based on clinical evaluation alone [23] . Considering the greater CT utilization rates in adults, use of this biomarker panel in adult patients might present an even greater opportunity for CT imaging reduction than the use in pediatric patients. Our data also suggests that for adults, the combination of a normal WBC and CRP may provide similar performance as a negative predictor as the biomarker panel, although previous studies have provided conflicting results [27] [28] [29] . The performance of the WBC/CRP combination in pediatric patients was less reliable [24] . The reason for this discrepancy between adult and pediatric patients is unclear, but may be related to the variability of normal WBC ranges across different pediatric age groups.
The prevalence of appendicitis in this adult cohort (19.0%) was somewhat lower than in our two previous pediatric studies (28.3% and 23.5%) [23, 24] . This is likely due to the higher frequency of other causes of abdominal pain such as acute gynecological diseases, diverticulitis, and kidney stones (shown in Table 1 ) which are more prevalent in the adult population, thereby diluting the frequency of acute appendicitis. This might decrease the potential impact of this test on reducing CT utilization rates for adult patients as a greater proportion may still require imaging in order to evaluate for other diseases despite negative biomarker panel results. However, US is already considered the imaging study of choice for some of these alternative diagnoses including gynecologic pathology, cholecystitis and, according to some authorities, renal colic in younger and low risk patients [33, 34] .
We also collected the treating physician's general clinical gestalt of the likelihood of acute appendicitis as low, medium, or high, and examined the performance of the biomarker panel stratified by that risk. We found sensitivity and NPV of the APPY1 test were both100% in the low risk group and slightly less in the medium and high risk groups. However, the numbers of patients in the medium and high risk groups were each progressively smaller resulting in substantially wider 95% confidence intervals. This results in substantial overlap of the 95% confidence intervals preventing any firm conclusions.
While the specificity of the biomarker panel is low, the test is not intended as a positive predictor as per previous reports [23, 24] . The clinical utility is in the rapid identification (test turnaround time 20-30 min) of a significant proportion of true negatives for whom appendicitis can be excluded with a high degree of certainty, which may alter subsequent decisions regarding imaging and/or treatment. As in pediatric patients, an inconclusive test result is not diagnostically helpful and should not be used to direct further diagnostic procedures or treatment which should be based on the clinical assessment. This test is also not indicated to evaluate for any diagnoses other than acute appendicitis. The combination of WBC/CRP provided somewhat greater specificity in this sample.
This study has several limitations. The patient population is a convenience sample and the institutional representation is weighted toward tertiary care centers which may not be representative of the adult Plasma samples were drawn and frozen at the clinical sites and shipped for testing at a central lab rather than tested on fresh samples in real time. However, previous studies revealed similar performance whether samples were frozen and shipped for central testing or tested onsite in real time using fresh plasma samples [23, 24] . The WBC values were obtained from the onsite clinical laboratory at each clinical site which may use different hematology analytic equipment and utilize different normal ranges. However, only the raw WBC values were used for the calculation of the biomarker panel results without regard to normal ranges at individual institutions. All labs were CLIA certified.
A small number of patients were lost to follow up. The reported performance characteristics of the biomarker panel would be affected if there were patients among this group who had false negative biomarker panel results.
While patients were enrolled prospectively, some of the clinical data was collected by subsequent review of the ED chart rather than by direct examination of the patient by study personnel. The subgroup analysis of the biomarker panel performance was also exploratory and was not defined a-priori, with the attendant limitations.
In conclusion, this biomarker panel exhibited high sensitivity and negative predictive value for acute appendicitis in an adult population presenting to the ED with abdominal pain, comparable to that previously demonstrated a pediatric and adolescent patients. Additionally, the combination of normal WBC and CRP in this adult sample provided similar performance to the biomarker panel as a negative predictor. This presents a potential opportunity to reduce the high rate of CT utilization for adult patients suspected of possible acute appendicitis. The actual impact on clinical care and imaging utilization in clinical practice, along with the relative performance of the biomarker panel compared to the WBC/CRP combination, remains uncertain and requires further investigation and validation.
